Biotech - Spark Newswire

4 minute read

Viking Therapeutics Announces Results From Phase 1 Clinical Trial Of Novel Oral Thyroid Receptor Beta Agonist VK0214; Says VK0214 ‘demonstrated encouraging safety and tolerability, as well as a predictable pharmacokinetic (PK) profile’

June 17, 7:07 AM

Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced results from the

VKTX

1 minute read

Biogen Discontinues Tau Antibody Program For Alzheimer’s After Mid-Stage Study Flops

By Vandana Singh

June 17, 6:54 AM

Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned.

BIIB

1 minute read

Why Are Cellect Biotechnology (APOP) Shares Surging Today?

By Vandana Singh

June 17, 6:49 AM

Cellect Biotechnology Ltd (NASDAQ:APOP) has filed a registration statement with the SEC in connection with its proposed strategic merger with privately-held Quoin…

APOP

1 minute read

Midatech Pharma Stock Jumps After Breakthrough Data On Encapsulation Of Biologic Using Q-Sphera

By Vandana Singh

June 17, 5:28 AM

Midatech Pharma PLC (NASDAQ: MTP) has announced a breakthrough in vitro data utilizing Q-Sphera technology and progress across multiple other programs. The technology showed potential to formulate proteins into long-acting injectable products.

MTP

1 minute read

Satsuma Stock Is Trading Higher As STS101 Shows Favorable Pharmacokinetic Profile, Tolerability In Early-Stage Study

By Vandana Singh

June 17, 5:25 AM

Satsuma Pharmaceuticals Inc (NASDAQ:STSA) announced positive Pharmacokinetic and safety results from a Phase 1 trial of STS101 (dihydroergotamine (DHE) nasal powder).…

STSA

2 minute read

Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data

By Shanthi Rexaline

June 17, 5:07 AM

German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ:

BNTX

1 minute read

Marker Therapeutics To Present At The Virtual Raymond James Human Health Innovation Conference Jun. 21

By Bill Haddad

June 16, 4:09 PM

ker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and

MRKR

2 minute read

UPDATE: Satsuma Says ‘All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile’; Co Initiating Phase 3 Efficacy Trial In Acute Treatment Of Migra…

By Bill Haddad

June 16, 4:07 PM

- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT Phase 3 efficacy trial to

STSA

1 minute read

PureTech Adds Inflammatory Disease Candidates To Pipeline With Alivio Buyout

By Vandana Singh

June 16, 1:54 PM

Four years after launching Alivio Therapeutics, PureTech Health plc (NASDAQ:PRTC) is bringing the hydrogel player back into the fold by acquiring the…

PRTC